A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04247126

Public ClinicalTrials.gov record NCT04247126. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .

Study identification

NCT ID: NCT04247126
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Syros Pharmaceuticals; Industry
Enrollment: 105 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 22, 2020
Primary completion: Jan 30, 2023
Completion: Mar 29, 2023
Last update posted: Oct 26, 2023

2020 – 2023

United States locations

U.S. sites: 16
U.S. states: 13
U.S. cities: 14

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	—
Cedars-Sinai Medical Center	Los Angeles	California	90048	—
University of California Los Angeles	Los Angeles	California	90095	—
Orlando Health Cancer Institute	Orlando	Florida	32806	—
Emory University	Atlanta	Georgia	30322	—
The University of Iowa	Iowa City	Iowa	52242	—
Johns Hopkins University	Baltimore	Maryland	21205	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
University of Michigan	Ann Arbor	Michigan	48109	—
START Midwest, LLC	Grand Rapids	Michigan	49546	—
Duke University	Durham	North Carolina	27705	—
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	—
Sidney Kimmel Cancer Center	Philadelphia	Pennsylvania	19107	—
Sarah Cannon Research Institute - Tennessee Oncology	Nashville	Tennessee	37203	—
South Texas Accelerated Research Theraputics (START), LLC	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04247126, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 26, 2023 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04247126 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →